Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
6.71
-0.14 (-2.04%)
At close: Apr 28, 2026, 4:00 PM EDT
6.70
-0.01 (-0.15%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Fennec Pharmaceuticals stock have an average target of 14.5, with a low estimate of 13 and a high estimate of 18. The average target predicts an increase of 116.10% from the current stock price of 6.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $13 | Buy | Reiterates | $13 | +93.74% | Apr 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $18 | Buy | Initiates | $18 | +168.26% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +93.74% | Aug 21, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +108.64% | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +93.74% | May 20, 2025 |
Financial Forecast
Revenue This Year
73.72M
from 44.64M
Increased by 65.12%
Revenue Next Year
104.00M
from 73.72M
Increased by 41.08%
EPS This Year
0.43
from -0.34
EPS Next Year
1.09
from 0.43
Increased by 153.75%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 83.1M | 120.3M | ||||||
| Avg | 73.7M | 104.0M | ||||||
| Low | 61.1M | 80.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 86.2% | 63.2% | ||||||
| Avg | 65.1% | 41.1% | ||||||
| Low | 36.8% | 8.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.97 | 1.64 | ||||||
| Avg | 0.43 | 1.09 | ||||||
| Low | 0.16 | 0.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 280.8% | ||||||
| Avg | - | 153.8% | ||||||
| Low | - | 70.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.